Current Report Filing (8-k)
April 15 2019 - 10:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): April 12, 2019
Patriot
Scientific Corporation
(Exact Name of Registrant as Specified
in Charter)
|
Delaware
|
|
0-22182
|
|
84-1070278
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
2038 Corte Del Nogal, Suite 141
Carlsbad, CA 92011-1478
(Address of Principal Executive Offices,
and Zip Code)
(760) 795-8517
Registrant’s Telephone Number,
Including Area Code
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Securities registered pursuant to Section
12(b) of the Act:
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communication pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On April 12, 2019, Patriot Scientific Corporation (the “Company”)
retained Artius Bioconsulting, a California limited liability company (“Artius”), to evaluate the potential of establishing
a systems integration company that develops a technology platform based on blockchain technology that could be implemented throughout
the drug development process (the “Project”) pursuant to a Consulting Agreement between the Company and Artius effective
as of April 12, 2019 (the “Agreement”).
Pursuant to the Agreement, Artius will research, analyze and
report its findings with respect to the Project in exchange for $151,000, payable in installments upon the completion of certain
deliverables to the Company. The deliverables are due at various times over the course of eight weeks. The Company will own the
Work Product (as defined in the Agreement). The Agreement has a term of four months, unless terminated earlier pursuant to its
terms.
The description of the Agreement herein is only a summary and
is qualified in its entirety by the full text of such document, which is filed as an exhibit hereto and is incorporated by reference
herein.
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
See Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Patriot Scientific Corporation
|
|
|
|
|
Date: April 15, 2019
|
By:
/s/ Clifford L. Flowers
|
|
|
Clifford L. Flowers
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX